Stockreport

ISCT Hails Landmark US FDA Approval of RYONCIL as Major Milestone for MSC Field [Yahoo! Finance]

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF Graft-versus-Host-Disease (GvHD). This is the first FDA approval of an MSC therapy in the US, marking a significant milestone for the field. RYONCIL will provide a treat [Read more]